Unknown PHASE2 INTERVENTIONAL 2-arm NCT00409227

Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy

Prospective Randomized Placebo Controlled Blinded Study to Evaluate the Efficacy of Alfuzosin (Alpha Blocker) on the Success Rates Following SWL.

Sponsor: Assaf-Harofeh Medical Center

Conditions Nephrolithiasis Ureterolithiasis Urolithiasis

Interventions Alpha blocker-alfuzosin placebo

Updated 6 times since 2017 Last updated: Jun 17, 2008 Started: Dec 31, 2006 Primary completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Nephrolithiasis and Ureterolithiasis and is currently ongoing. Assaf-Harofeh Medical Center leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assaf-Harofeh Medical Center

Data source: Assaf-Harofeh Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ẕerifin, Israel